TriangleFruquintinib+ Lonsurf (trifluridine… (NCT06992258)
Fruquintinib+ Lonsurf (trifluridine and tipiracil) trial for Colorectal Cancer (NCT06992258). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic, mismatch-repair-proficient colorectal cancer after required chemotherapy and indicated antibody treatments. BRAF V600 mutations and previous regorafenib, TAS-102 or fruquintinib are excluded.
The idea: compare fruquintinib alone with fruquintinib plus TAS-102. Fruquintinib blocks VEGF receptors involved in blood-vessel growth. TAS-102 combines trifluridine, which disrupts DNA processes, with tipiracil, which slows its breakdown. These oral treatments are tested for time without progression. Entry requires progression on, or intolerance of, the last regimen.
This phase 2 study plans 120 patients. Criterium sponsors thirteen recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.